Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02KAW
|
||||
| Former ID |
DNCL001700
|
||||
| Drug Name |
CDP-7657
|
||||
| Synonyms |
CD40L
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Systemic lupus erythematosus [ICD9: 710; ICD10:M32] | Phase 1 | [522990] | ||
| Company |
Biogen Idec
|
||||
| Target and Pathway | |||||
| Target(s) | Tumor necrosis factor ligand superfamily member 5 | Target Info | [533182], [533313] | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| NF-kappa B signaling pathway | |||||
| Cell adhesion molecules (CAMs) | |||||
| T cell receptor signaling pathway | |||||
| Intestinal immune network for IgA production | |||||
| Malaria | |||||
| Toxoplasmosis | |||||
| Asthma | |||||
| Autoimmune thyroid disease | |||||
| Systemic lupus erythematosus | |||||
| Allograft rejection | |||||
| Primary immunodeficiency | |||||
| Viral myocarditis | |||||
| References | |||||
| Ref 533182 | First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus. 2015 Sep;24(10):1045-56. | ||||
| Ref 533313 | CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015 Sep 3;17:234. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.